form15.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 000-27937
DRAGON PHARMACEUTICAL INC.
(Exact name of registrant as specified in its charter)
650 West Georgia Street, Suite 310
Vancouver, British Columbia Canada V6B 4N9
(604) 669-8817
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
Common Stock, $.001 par value
(Title of each class of securities covered by this form)
None
(Titles of all other classes of securities for which a duty to file reports under
section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1)
|
[X]
|
|
Rule 12g-4(a)(2)
|
[ ]
|
|
Rule 12h-3(b)(1)(i)
|
[X]
|
|
Rule 12h-3(b)(1)(ii)
|
[ ]
|
|
Rule 15d-6
|
[ ]
|
Approximate number of holders of record as of the certification or notice date: 2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Dragon Pharmaceutical Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
|
DATE: July 22, 2010
|
By:
|
/s/ Yanlin Han |
| |
Name: Yanlin Han
Title: Chief Executive Officer
|